(Q33595085)

28 July 2017

title

The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors (English)

1 reference

28 July 2017

1 reference

1 reference

1 reference

1 reference

2

Ian F Tannock

1 reference

28 July 2017

Carol M Lee

1

1 reference

28 July 2017

language of work or name

English

0 references

publication date

3 June 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

10

1 reference

28 July 2017

page(s)

255

1 reference

Factors determining antibody distribution in tumors

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Drug resistance and the solid tumor microenvironment

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Trastuzumab--mechanism of action and use in clinical practice

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Drug penetration in solid tumours

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

The ErbB/HER receptor protein-tyrosine kinases and cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Monoclonal antibodies as therapeutic agents for cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Epidermal growth factor receptor-targeted therapy in colorectal cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Trastuzumab: hopes and realities

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Switching signals on or off by receptor dimerization

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Epidermal growth factor-related peptides and their receptors in human malignancies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Transport of molecules in the tumor interstitium: a review

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors.

14 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-255

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-255

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-255

Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-255

Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889896

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients

30 October 2018

1 reference

12 December 2020

Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts

1 reference

12 December 2020

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

12 December 2020

Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors

1 reference

12 December 2020

Detection of hypoxia in human squamous cell carcinoma by EF5 binding

1 reference

12 December 2020

Regulation of tumour drug delivery by blood flow chronobiology

1 reference

12 December 2020

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules

1 reference

12 December 2020

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

1 reference

12 December 2020

Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors

1 reference

12 December 2020

Autoradiographic analysis of monoclonal antibody distribution in human colon and breast tumor xenografts

1 reference

12 December 2020

Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids

1 reference

12 December 2020

Epidermal growth factor receptors in lung tumours

1 reference

12 December 2020

Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification

1 reference

12 December 2020

Barriers to drug delivery in solid tumors

1 reference

12 December 2020

Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model

1 reference

12 December 2020

Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250

1 reference

12 December 2020

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-10-255

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference